DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Seasonal Allergic Rhinitis

Intervention: SCH 900538 (Drug); Pseudoephedrine (Drug); Placebo Capsules (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.

Summary

This study is to evaluate the effectiveness of a new drug on congestion in subjects with seasonal allergic rhinitis. This effect will be compared to placebo and to the decongestant, pseudoephedrine.

Clinical Details

Official title: Study of the Decongestant Effect of SCH 900538 Compared With Placebo and Pseudoephedrine as Active Control in Subjects With Seasonal Allergic Rhinitis (SAR) Exposed to Pollen in an Environmental Exposure Unit

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Average change from baseline in nasal congestion scores over the first 4-hour observation period.

Secondary outcome:

Average change from baseline in nasal congestion at each evaluation time point.

Average change from baseline in total symptoms, total symptoms minus congestion, total nasal symptoms, total nasal symptoms minus congestion, total non-nasal symptoms, and individual symptoms scores.

Onset of action: defined as the first time point at which a sustained, statistically significant (P<=0.05) reduction relative to placebo in an efficacy variable (eg, nasal congestion) up to a pre-specified time point.

Average change from baseline in PNIF over the first 4-hour and 12-hour study periods and at each time point.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subjects must be 18 to 65 years of age, of either sex, and of any race.

- Subjects must have a history of SAR due to ragweed for the last two consecutive

ragweed seasons.

- Subjects must be skin-test positive for the ragweed pollen allergen used in the

Environmental Exposure Unit (pollen chamber at the Screening Visit or within 12 months prior to the Screening Visit.

- Subjects must develop a pre-defined severity of allergy symptoms within 90-minute

after entering the pollen chamber during the pollen challenge at the Priming visit (Visit 2), and prior to dosing (Visit 3), in order to qualify for the study.

- Female subjects of childbearing potential must have a negative serum pregnancy test

at Screening and a negative urine pregnancy test prior to randomization at the Treatment Visit. Female subjects and female partners of male subjects must be using an acceptable form of birth control during the study.

- Blood pressure and pulse rate must be within normal ranges.

Exclusion Criteria:

- Subjects who have had an upper or lower respiratory tract infection within

approximately 28 days (4 weeks) before Priming (Visit 2) and thereafter.

- Subjects who have a dependence upon nasal, oral, or ocular decongestants, nasal

topical antihistamines, or nasal steroids, in the opinion of the investigator.

- Subjects with any clinically significant condition or situation, other than the

condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.

- Subjects who have used any investigational drugs, including placebo, within 30 days

of Screening or for the duration of this stud, or who are participating in any other clinical study.

- Subjects with a history of rhinitis medicamentosa.

- Subjects with a history of anaphylaxis or severe or serious reaction to skin testing.

- Subjects who are being medically treated for any of the following conditions:

narrow-angle glaucoma, increased intraocular pressure, urinary retention, hypertension, severe coronary artery disease, ischemic heart disease, diabetes mellitus, hyperthyroidism, renal impairment, or prostatic hypertrophy; current treatment with monoamine oxidase (MAO) inhibitors.

- Subjects with a history of a positive test, or are symptomatic, for HIV, TB (not due

to vaccination), and hepatitis B (not due to vaccination) or hepatitis C.

- Subjects with asthma that requires medication other than occasional (<=3 uses per

week) use of an inhaled short-acting b-2 agonist.

Locations and Contacts

Additional Information

Starting date: May 2008
Last updated: October 13, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017